Viridian Therapeutics announces $150M common stock and preferred stock offering

Viridian Therapeutics announced that it has commenced an underwritten public offering of $150M of shares of its common stock and Series B non-voting convertible preferred stock. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes. Jefferies, Goldman Sachs & Co., Stifel and RBC Capital Markets are acting as joint book-running managers for the offering. Wedbush PacGrow is also acting as co-manager for this offering.